A LAT1 inhibitor, nanvuranlat (J-Pharma), significantly increased progression-free survival (PFS) rates among patients with highly refractory biliary tract cancer compared with placebo, according to new research. Results of the phase 2 study presented at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (abstract 494) are promising for patients with this advanced, difficult-to-treat malignancy, the researchers said.
“Current treatments in later
FEBRUARY 22, 2023